Population‐level impact of expanding PrEP coverage by offering long‐acting injectable PrEP to MSM in three high‐resource settings: a model comparison analysis

INTRODUCTION: Long‐acting injectable cabotegravir (CAB‐LA) demonstrated superiority to daily tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre‐exposure prophylaxis (PrEP) in the HPTN 083/084 trials. We compared the potential impact of expanding PrEP coverage by offering CAB‐LA to men...

Descripción completa

Detalles Bibliográficos
Autores principales: Stansfield, Sarah E., Heitner, Jesse, Mitchell, Kate M., Doyle, Carla M., Milwid, Rachael M., Moore, Mia, Donnell, Deborah J., Hanscom, Brett, Xia, Yiqing, Maheu‐Giroux, Mathieu, van de Vijver, David, Wang, Haoyi, Barnabas, Ruanne, Boily, Marie‐Claude, Dimitrov, Dobromir T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339001/
https://www.ncbi.nlm.nih.gov/pubmed/37439080
http://dx.doi.org/10.1002/jia2.26109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10339001/
https://www.ncbi.nlm.nih.gov/pubmed/37439080
http://dx.doi.org/10.1002/jia2.26109

Ejemplares similares